Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: From bench to bedside

Oncologist

Volumn 17, Issue 5, 2012, Pages 694-707

  Mato, Anthony R ^a   Feldman, Tatyana ^a   Goy, André ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Carfilzomib; Lymphoma; Marizomib; Non Hodgkin's; ONX 0912

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IXAZOMIB CITRATE; LENALIDOMIDE; METHOTREXATE; OBATOCLAX; OPROZOMIB; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL DISEASE; HUMAN; HYPONATREMIA; HYPOXIA; IMMUNOTHERAPY; INFECTION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; LYMPHOMA, NON-HODGKIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84861602611     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0341     Document Type: Article

References (163)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society, 2012: 1-64.
2. National Cancer Institute. SEER Stat Fact Sheets-Non-Hodgkin Lymphoma. Bethesda, MD: National Cancer Institute, seer.cancer.gov/statfacts/html/nhl. html, accessed April 16, 2012.
3. Ansell SM, Armitage J. Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc 2005;80: 1087-1097.
4. Morton LM, Wang SS, Devesa SS et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
5. Goy A, Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma 2007;7(suppl 5):S 184-5191.
6. Prichard M, Harris T, Williams ME et al. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 2009; 10:983-995.
7. Gisselbrecht C, Vose J, Nademanee A et al. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: In pursuit of a complete response. The Oncologist 2009;14(suppl 2):41-51.
8. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360.
9. Pham LV, Tamayo AT, Yoshimura LC et al. Inhibition of constitutive NF-κ B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95.
10. Strauss SJ, Higginbottom K, JÏiger S et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007; 67:2783-2790.
11. Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005;4:77-82.
12. Satou Y, Nosaka K, Koya Y et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004;18:1357-1363.
13. Nasr R, El-Sabban ME, Karam JA et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005;24:419-430.
14. Shen L, Au WY, Guo T et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: An in vitro and in vivo preclinical evaluation. Blood 2007;110:469-470.
15. Bonvini P, Zorzi E, Basso G et al. Bortezomibmediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007;21:838-842.
16. Perez-Galàn P, Roué G, Villamor N et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107: 257-264.
17. Kabore AF, Sun J, Hu X et al. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006;11:1175-1193.
18. Rizzatti EG, Mora-Jensen H, Weniger MA et al. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-KB pathways. Leuk Lymphoma 2008;49:798-808.
19. Ishii Y, Pirkmaier A, Alvarez JV et al. Cyclin Dl overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006;98:1238-1247.
20. O'Connor OA, Smith EA, Toner LE et al. The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006;12:2902-2911.
21. Labussière M, Pinel S, Vandamme M et al. Radiosensitizing properties of bortezomib depend on therapeutic schedule. Int J Radiat Oncol Biol Phys 2011;79: 892-900.
22. Kamer S, Ren Q, Dicker AP. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor Velcade (bortezomib, PS-341). Arch Gynecol Obstet 2009;279:41-46.
23. Ahn KS, Sethi G, Chao TH et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through downmodulation of NF-KB regulated gene products. Blood 2007;110:2286-2295.
24. O'Connor OA, Stewart AK, Vallone M et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-7091.
25. Ruiz S, Krupnik Y, Keating M et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5:1836-1843.
26. Roccaro AM, Sacco A, Aujay M et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010;115:4051-4060.
27. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70:1970-1980.
28. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006;95:961-965.
29. Kuhn DJ, Chen Q, Voorhees PM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-3290.
30. Williamson MJ, Blank JL, Bruzzese FJ et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 2006;5:3052-3061.
31. Chauhan D, Catley L, Li G et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005;8:407-419.
32. Miller CP, Ban K, Dujka ME et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROSdependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110: 267-277.
33. Potts BC, Albitar MX, Anderson KC et al. Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011;11:254-284.
34. Dick LR, Fleming PE. Building on bortezomib: Second-generation proteasome inhibitors as anti cancer therapy. Drug Discov Today 2010;15:243-249.
35. Chauhan D, Singh AV, Aujay M et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010;116:4906-4915.
36. Dreyling M. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl5):vl81-v183.
37. Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl5):v172-v174.
38. Weigert O, Pastore A, Rieken M et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007;21:524-528.
39. Kapanen A, Tucker C, Chikh G et al. Cell based assays completed with the mantle cell lymphoma cell lines Z138 and NCEB-1 indicate that combinations of bortezomib and flavopiridol interact to achieve synergistic activity [abstract]. Blood 2005;106:Abstract 2410.
40. Wadehra N, Lin T, Ryan T et al. Combination bortezomib (PS341, Velcade) and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma [abstract]. Blood 2005;106:Abstract 2407.
41. Wang M, Han XH, Zhang L et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008;22:179-185.
42. Alinari L, White VL, Earl CT et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs 2009;1:31-40.
43. O' Connor O, Toner L, Smith E et al. Combined targeting of the proteasome and Bcl-2 sensitizes human B-cell lymphoma and multiple myeloma to cyclophosphamide in in vitro and in vivo models of these diseases [abstract]. Blood 2004;104:Abstract 2484.
44. Yazbeck VY, Georgakis GV, Li Y et al. Inhibition of the Pan-Bcl-2 family by the small molecule GX15-070 induces apoptosis in mantle cell lymphoma (MCL) cells and enhances the activity of two proteasome inhibitors (NPI-0052 and bortezomib), and doxorubicin chemotherapy [abstract]. Blood 2006;108:Abstract 2532.
45. Shore G, Watson M, Roulston A et al. Obatoclax (GX15-070) is a potent antagonist of constitutive Mcl1/Bak interactions in intact mitochondrial membrane and synergizes with bortezomib in mantle cell lymphoma [abstract]. Blood 2006;108:Abstract 832.
46. Gruber EA, Czuczman MS, Olejniczak SH et al. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens [abstract]. Blood 2007;110:Abstract 1389.
47. Perez-Galàn P, Roué G, Villamor N et al. The BH3mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-4449.
48. Perez-Galàn P, Roué G, Lopez-Guerra M et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008;22:1712-1720.
49. Paoluzzi L, Gonen M, Bhagat G et al. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906-2916.
50. Antun A, Cerchietti L, Aparo S et al. BCL6 inhibitor peptide have powerful anti-lymphoma activity in animal models of diffuse large B-cell lymphoma and synergize with other anti-lymphoma drugs [abstract]. Blood 2006;108:Abstract 827.
51. Ackler S, Mitten MJ, Foster K et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 2010;66:869-880.
52. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclindependent kinase inhibitor flavopiridol through a SAPK/ JNK- and NF-KB-dependent process. Oncogene 2003; 22:7108-7122.
53. Ismail LK, Timm M, Novak A et al. Rapamycin enhances the cytotoxicity of bortezomib and rituximab on mantle cell lymphoma (MCL) cell lines [abstract]. Blood 2005;106:Abstract 2411.
54. Haritunians T, Mori A, O' Kelly J et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007;21:333-339.
55. Maharaj L, Popat R, Chahwan A et al. The novel HDAC inhibitor UCL67022 is highly potent in multiple myeloma and non-Hodgkin's lymphoma and is enhanced by bortezomib [abstract]. Blood 2006;108:Abstract 2604.
56. Bhalla S, David K, Mauro L et al. Histone deacetylase inhibitor (HDACi) PCI-24781 and bortezomib result in synergistic apoptosis in Hodgkin lymphoma (HL) and non-Hodgkin's lymphoma (NHL) cell lines: Investigation of cell death and NFKB-mediated pathways [abstract]. Blood 2007;110:Abstract 3589.
57. Heider U, von Metzler I, Kaiser M et al., Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008;80:133-142.
58. Rao R, Fiskus W, Joshi R et al. Targeting histone deacetylases and unfolded protein mediated endoplasmic reticulum (ER) stress as a strategy against human mantle cell lymphoma [abstract]. Blood 2007;110: Abstract 1378.
59. Paoluzzi L, Scotto L, Marchi E et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010; 16:554-565.
60. Hernandez-Ilizaliturri FJ, Mavis C, Maraj I et al. Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the anti-tumor activity of bortezomib (BTZ) in rituximab-chemotherapy sensitive and resistant lymphoma cell lines [abstract]. Blood 2010;116: Abstract 3936.
61. Rao R, Fiskus W, Balusu R et al. Treatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib [abstract]. Blood 2010;116:Abstract 2856.
62. Dasmahapatra G, Lembersky D, Friedberg JW et al. Histone deacetylase inhibitors potentiate the lethality of the irreversible proteasome inhibitor carfilzomib in mantle cell lymphoma cells in vitro and in vivo [abstract]. Blood 2010;116:Abstract 3938.
63. Paoluzzi L, Scotto L, Marchi E et al. The antihistaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol 2009;146:656-659.
64. Rao R, Nalluri S, Fiskus W et al. Role of CAAT/ enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res 2010;16:4742-4754.
65. Jia X, Leleu X, Moreau AS et al. The proteasome inhibitor NPI-0052 in combination with bortezomib induces antitumor activity in Waldenstrom macroglobulinemia [abstract]. Blood 2006;108:Abstract 4746.
66. Roccaro A, Leleu X, Sacco A et al. The combination of bortezomib and NPI-0052 exerts anti-tumor activity in Waldenstrom macroglobulinemia (WM) [abstract]. Blood 2007;110:Abstract 1516.
67. Leleu X, O'Sullivan G, Jia X et al. Novel agent perifosine enhances antitumor activity of bortezomib, rituximab and other conventional therapies in Waldenstrom's macroglobulinemia [abstract]. Blood 2006;108: Abstract 2517.
68. Moreau AS, Jia X, O'Sullivan G et al. The selective protein kinase CB inhibitor, enzastaurin, induces in vitro and in vivo antitumor activity in Waldenstrom's macroglobulinemia [abstract]. Blood 2006;108:Abstract 2496.
69. Pham LV, Tamayo AT, Li C et al. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: Therapeutic implications. Mol Cancer Ther 2010;9:2026-2036.
70. Roué G, Perez-Galàn P, Mozos A et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011;117:1270-1279.
71. Busse A, Kraus M, Na IK et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 2008;112:659-670.
72. Pervan M, Calimlim J, Matso D et al. Active combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model [abstract]. Blood 2005;106: Abstract 2406.
73. Roué G, Perez-Galàn P, Lopez-Guerra M et al. Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007;178:1923-1930.
74. Georgakis GV, Li Y, Humphreys R et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130: 501-510.
75. Smith MR, Jin F, Joshi I. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosisinducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 2007;13:5528s-5534s.
76. Romaguera JE, Fayad LE, Feng L et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150:200-208.
77. Evens AM, Winter JN, Hou N et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: Long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2008;140:385-393.
78. Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
79. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992.
80. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26: 4473-4479.
81. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23: 3383-3389.
82. Jermann M, Jost LM, Taverna C et al. RituximabEPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study. Ann Oncol 2004;15:511-516.
83. Morschhauser F, Dreyling M, Rohatiner A et al. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence. The Oncologist 2009;14(suppl 2):17-29.
84. Jaeger G, Neumeister P, Brezinschek R et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: A phase II study. Eur J Haematol 2002; 69:21-26.
85. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
86. Orlowski RZ, Voorhees PM, Garcia RA et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105: 3058-3065.
87. O' Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
88. Strauss SJ, Maharaj L, Hoare S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-2112.
89. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675.
90. Faderl S, Rai K, Gribben J et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006;107:916-924.
91. Belch A, Kouroukis CT, Crump M et al. A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-121.
92. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24: 4867-4874
93. Goy A, Bernstein SH, Kahl BS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20: 520-525.
94. O'Connor OA, Moskowitz C, Portlock C et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial. Br J Haematol 2009;145:34-39.
95. Goy A, Bernstein SH, McDonald A et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010;51:1269-1277.
96. Alsina M, Trudel S, Vallone M et al. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [abstract]. Blood 2007; 110:Abstract 411.
97. Orlowski RZ, Stewart K, Vallone M et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: Phase 1 results [abstract]. Blood 2007;110:Abstract 409.
98. Aghajanian CA, Hamlin P, Gordon MS et al. Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors. J Clin Oncol 2008;26(15 suppl):Abstract 3574.
99. Baiocchi RA, Alinari L, Lustberg ME et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011;117:2355-2581.
100. Agathocleous A, Rohatiner A, Rule S et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010; 151:346-353.
101. Chiappella A, Pregno P, Zinzani PL et al. Weekly infusion of bortezomib in combination with rituximab in relapsed/refractory indolent non-follicular and mantle cell lymphoma is safe and effective: Two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi (IIL) [abstract]. Blood 2010;116:Abstract 3965.
102. Morrison VA, Johnson JL, Jung S et al. A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. J Clin Oncol 2010; 28(15 suppl):Abstract 8106.
103. Beaven AW, Shea TC, Moore DT et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/ refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2012;53:254-258.
104. Snell M, Koc ON, Bahlis NJ et al. A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 2006;24(18 suppl):Abstract 7580.
105. Weigert O, Weidmann E, Mueck R et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma-long-term results of a multi-center observation study. Leuk Lymphoma 2009;50: 716-722.
106. Kouroukis CT, Fernandez LA, Crump M et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leul Lymphoma 2011;52:394-399.
107. Orciuolo E, Buda G, Pelosini M et al. Fludarabine, bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. Br J Haematol 2010;148:810-812.
108. Musty PM, Guariglia R, Pietrantuono G et al. A pilot study with rituximab, bortezomib and hyper-fractionated cyclophosphamide (RBC regimen) for the treatment of advanced mantle cell lymphoma in elderly patients. Haematologica 2008;93(suppl 1):Abstract 0273.
109. Gerecitano J, Portlock CS, Hamlin PA Jr et al. Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas [abstract]. Blood 2009; 114:Abstract 3708.
110. Friedberg JW, Vose JM, Kelly JL et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-2812.
111. Drach J, Kaufmann H, Pichelmayer O et al. Bortezomib, rituximab, and dexamethasone (BORID) as salvage treatment in relapsed/refractory mantle cell lymphoma: Sustained disease control in patients achieving a complete remission [abstract]. Blood 2007;110: Abstract 2578.
112. Gressin R, Houot R, Uribe MO et al. Final results of the RiPAD+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma. A phase II prospective study of the GOELAMS group [abstract]. Blood 2010;116:Abstract 2791.
113. Romaguera J, Fayad L, McLaughlin P et al. Phase I trial of bortezomib in combination with rituximabhyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma [abstract]. Blood 2008;112: Abstract 3051.
114. Romaguera JE, Fayad LE, McLaughlin P et al. Phase I trial of bortezomib in combination with rituximab-hyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 2010;151:47-53.
115. Kahl B, Chang J, Eickhoff J et al. VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: A phase II study from the Wisconsin oncology network [abstract]. Blood 2008;112: Abstract 265.
116. Goy A, Ford P, Feldman T et al. A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma [abstract]. Blood 2007;110:Abstract 2569.
117. Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: The old and the new. Semin Hematol 2008;45(suppl 2):S2-S6.
118. Paoluzzi L, O'Connor OA. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006;20:13-23.
119. Di Bella N, Taetle R, Kolibaba K et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475-480.
120. Ribrag V, Tilly H, Casasnovas O et al. Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d'Etude des Lym- phomes de l'Adulte (GELA) study FL-05 [abstract]. Blood 2010;116:Abstract 768.
121. O'Connor OA, Portlock C, Moskowitz C et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010; 16:719-726.
122. de Vos S, Goy A, Dakhil SR et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009;27:5023-5030.
123. Coiffier B, Osmanov EA, Hong X et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12:773-784.
124. Coiffier B, Li W, Henitz ED et al. Identification of patient subgroups demonstrating longer progressionfree survival (PFS) benefit with bortezomib-rituximab versus rituximab in patients with relapsed or refractory follicular lymphoma (FL): biomarker analyses of the phase 3 LYM3001 study [abstract]. Blood 2011;118: Abstract 265.
125. Theocharous P, Shpilberg O, Elsayed YA. A randomized, open-label, multicenter phase II study of bortezomib with fludarabine in comparison to rituximab with fludarabine in follicular lymphoma subjects previously treated with rituximab. J Clin Oncol 2010;28(15 suppl):Abstract TPS303.
126. Barr PM, Fu P, Lazarus HM et al. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 2009;147:89-96.
127. Friedberg JW, Vose JM, Kelly JL et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): A multicenter phase II clinical trial [abstract]. Blood 2009;114:Abstract 924.
128. Fowler N, Kahl BS, Lee P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 2011;29:3389-3395.
129. Craig M, Hanna WT, Cabanillas F et al. Bortezomib in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma: Results of a phase 2 study [abstract]. Blood 2010;116:Abstract 2798.
130. Sehn LH, Macdonald D, Rubin S et al. Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2011;29:3396-3401.
131. Salles G. Is there a role for bortezomib combinations in the management of patients with follicular lymphoma? J Clin Oncol 2011;29:3349-3350.
132. Nabhan C, Dalal N, Tolzien K et al. Bortezomib (Velcade), rituximab, cyclophosphamide, dexamethasone (VRCD) combination therapy in front-line lowgrade non-Hodgkin lymphoma (LG-NHL) is active in elderly patient population [abstract]. Blood 2010;116: Abstract 1769.
133. Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-2724.
134. Fu K, Weisenburger DD, Choi WW et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and nongerminal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
135. Fitoussi O, Belhadj K, Mounier N et al. Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA. Haematologica 2011; 96:1136-1143.
136. van Imhoff GW, Boerma EJ, van der Holt B et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-4142.
137. Hong J, Park S, Park J et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma 2011;52: 1904-1912.
138. Milhollen MA, Traore T, Adams-Duffy J et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-KB-dependent lymphoma. Blood 2010;116:1515-1523.
139. Dunleavy K, Janik J, Gea-Banacloche J et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma [abstract]. Blood 2004;104:Abstract 1385.
140. Jang G, Sym SJ, Kim S et al. A phase I trial of bortezomib plus CHOP every 2 weeks in patients with advanced stage diffuse large B-cell lymphomas [abstract]. Blood 2007;110:Abstract 4446.
141. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.
142. Mounier N, Ribrag V, Haioun C et al. Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). J Clin Oncol 2007; 25(18 suppl):Abstract 8010.
143. Dunleavy K, Pittaluga S, Czuczman MS et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6076.
144. Doner K, Flinn IW, Ulrich BK et al. Rapid prospective identification of non-germinal center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) patients for targeted trials: Early results from PYRAMID, a phase 2 randomized study of R-CHOP ±- bortezomib in newly diagnosed non-GCB DLBCL [abstract]. Blood 2010;116:Abstract 1792.
145. Treon SP, Ioakimidis L, Soumerai JD et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:3830-3835.
146. Ghobrial IM, Matous J, Padmanabhan S et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia [abstract]. Blood 2008;112:Abstract 832.
147. Lee J, Suh C, Kang HJ et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008;19:2079-2083.
148. Evens AM, Gordon LI, Patton D et al. Phase I results of combination gemcitabine and bortezomib (Velcade®) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL) [abstract]. Blood 2008;112:Abstract 2005.
149. Dhillon N, Bakkannagari S, Ng C et al. Cutaneous T cell lymphoma: Responses in phase 1 trial of combination therapy with liposomal doxorubicin, bortezomib, and gemcitabine [abstract]. Blood 2006;108:Abstract 2466.
150. Delmer A, Fitoussi O, Gaulard P et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial. J Clin Oncol 2009;27(15 suppl):Abstract 8554.
151. Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-4297.
152. Marchi E, Paoluzzi L, Scotto L et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010;16:3648-3658.
153. Styczynski J, Einsele H, Gil L et al. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases. Transpl Infect Dis 2009;11:383-392.
154. Zou P, Kawada J, Pesnicak L et al. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EB V-transformed B cells. J Virol 2007;81:10029-10036.
155. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: Carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 2011;11:285-295.
156. Kuhn DJ, Hunsucker SA, Chen Q et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009;113: 4667-4676.
157. Utecht KN, Kolesar J. Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 2008;65:1221-1231.
158. Suh KS, Goy A. Bortezomib in mantle cell lymphoma. Future Oncol 2008;4:149-168.
159. Agathocleous A, Rule S, Johnson P et al. Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom' s macroglobulinaemia [abstract]. Blood 2007;110:Abstract 2559.
160. Moosmann PR, Heizmann M, Kotrubczik N et al. Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkin's lymphoma: A single-center phase 1/2 study [abstract]. Blood 2008;112:Abstract 1574.
161. Richardson PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-3120.
162. Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-440.
163. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762.